{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-268057","form_type":"8-K","ticker":"IVVD","cik":"0001832038","company_name":"Invivyd, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.693566+00:00","generated_at":"2026-05-16T23:58:31.779755+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Invivyd Q3 revenue $13.1M (+41% YoY); net loss narrows; IND cleared for VYD2311","bullets":["PEMGARDA net product revenue $13.1M in Q3 2025, up 41% YoY and 11% QoQ.","Net loss $10.5M ($0.06 diluted EPS) vs $60.7M ($0.51) in Q3 2024; R&D spend fell to $8.0M from $57.9M.","Cash $85.0M at Sep 30; >$100M after Oct ATM; $57.5M gross proceeds from Aug 2025 offering.","FDA cleared IND for VYD2311; pivotal REVOLUTION program (DECLARATION N=1770, LIBERTY N=210) starts near year-end 2025, data mid-2026.","Board adds Dr. Paul Bolno; Kristie Kuhl named CCO; pipeline expansion into RSV and measles."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-268057","json":"https://secwatch.observer/filing/0001193125-25-268057.json","markdown":"https://secwatch.observer/filing/0001193125-25-268057.md","text":"https://secwatch.observer/filing/0001193125-25-268057.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1832038/000119312525268057/0001193125-25-268057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1832038/000119312525268057/d81968d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:58:31.779755+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}